The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
Experts who took part in Patient-Centered Oncology Care® 2021 said when guidelines recommend high-cost targeted therapies or immunotherapies, the focus must turn to areas such as imaging, diagnostic tests, and other elements that contribute to the cost of care.
With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.
DOI: 10.37765/ajmc.2021.88735
Biomarker testing and remote patient monitoring are just 2 areas of research presented during the annual meeting of the American Society of Clinical Oncology (ASCO).
In the inaugural Oncology Value Coalition from The American Journal of Managed Care®, Kashyap Patel, MD, led a discussion with Debra Patt, MD, PhD, MBA; and Karen Winkfield, MD, PhD, exploring findings that suggest minority groups develop cancer at higher rates and experience worse outcomes than nonminority groups.
In the inaugural Oncology Value Coalition from The American Journal of Managed Care®, Kashyap Patel, MD, led a discussion with Debra Patt, MD, PhD, MBA; and Karen Winkfield, MD, PhD, exploring findings that suggest minority groups develop cancer at higher rates and experience worse outcomes than nonminority groups.
In the inaugural Oncology Value Coalition from The American Journal of Managed Care®, Kashyap Patel, MD, led a discussion with Debra Patt, MD, PhD, MBA; and Karen Winkfield, MD, PhD, exploring findings that suggest minority groups develop cancer at higher rates and experience worse outcomes than nonminority groups.
Lalan Wilfong, MD, executive vice president, Value Based Care & Quality Programs, Texas Oncology, and co-chair, Payment Reform, Community Oncology Alliance, discusses implications of quality metrics in cancer care and what perspectives on the topic he is looking forward to hearing at the 2021 Community Oncology Conference.
The US Oncology Network continues its rapid growth and enhances surgical expertise with addition of physicians from Texas Colon & Rectal Specialists as a part of Texas Oncology
In today's managed care environment, it is important that contracts between practices and payers include reciprocal language that affords a practice protection over processes, decisions, and changes to the agreement over time, while aligning with its business operation.
The Network enrolled its 100,000th patient in the Oncology Care Model (OCM) recently, and its practices are finding success in the complicated model.
The US Oncology Network reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare & Medicaid Innovation’s (CMMI) Oncology Care Model (OCM)
COVID-19 has created a significant distraction from normal practice operations. The uncertainty that comes along with the pandemic is a huge worry, and can distract from practice transformation.
The authors, from RxCrossroads by McKesson, discuss the impact of copay accumulator and maximizer programs.
As health care costs rise, especially for patients with complex conditions, a major barrier to access is the disconnect between medical benefits and pharmacy benefits.
Available in patients’ own communities, novel clinical trials are making an impact in the fight against cancer.
Gavreto was granted accelerated approval by the FDA on September 4, 2020, for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC).
Inqovi was approved by the FDA on July 7, 2020, for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).
The CDC is exercising an option of an existing contract with McKesson for this effort.